Introduction
G protein-coupled receptors (GPCRs) comprise a large family of cell surface receptors that are activated in response to a wide array of extracellular stimuli (van Biesen et al., 1996; Gutkind, 1998) . Members of the family have a common tertiary structure characterized by seven transmembrane domains linked by extra-and intra-cellular loops. GPCRs associate with and activate heterotrimeric G proteins. Heterotrimeric G proteins are comprised of three heterologous subunits (Ga, Gb and Gg) that only associate when the Ga unit is in the biologically inactive GDP-bound form. A non-covalent interaction between the G protein and an activated receptor causes the exchange of GDP for activating GTP on the Ga unit, thus causing it to become associated from the Gbg dimer. This generates two functional units each capable of stimulating a distinct array of eector functions.
In addition to their normal physiological functions, there is substantial evidence that the deregulated expression of heterotrimeric G proteins and their receptors is sucient for cellular growth transformation (Gutkind, 1998; Dhanasekaran et al., 1995 Dhanasekaran et al., , 1998 . Many ligands that act via GPCRs have been shown to induce mitogenic responses in a variety of cell types. Furthermore there is increasing evidence that some GPCRs harbor oncogenic potential. For example, the mas and g2a oncogenes, both of which encode GPCRs, were isolated based on their transforming activity (Young et al., 1988; Zohn et al., 2000) . The serotonin 5HT1b receptor (Julius et al., 1989) and the M 1 , M 3 and M 5 subtypes of the acetyl cholinergic receptors (Gutkind et al., 1991) were found to cause agonistdependent transformation, and constitutively-activated mutants of the a1B-adrenergic receptor have been shown to increase focus formation in NIH3T3 cell assays (Allen et al., 1991) . Finally, recent studies have revealed the transforming potential of constitutively activated derivatives of Ga subunits in a variety of cell types. In particular, constitutively activated mutants of Ga 12 and the related Ga 13 have exhibited the strongest transforming potential and can cause tumorigenic transformation of rodent ®broblasts (Xu et al., 1993; Vara Prasad et al., 1994; Chan et al., 1993; Jiang et al., 1993; Voyno-Yasenetskaya et al., 1994) . Transforming activity has also been observed for activated mutants of Ga l and Ga q (Gupta et al., 1992; Kalinec et al., 1992; De Vivo et al., 1992) .
Thrombin is a serine protease with multiple physiological eects (Van Obberghen-Schilling and PouysseÂ gur, 1993; Coughlin, 1993) . Although the best described function of thrombin concerns its role in the regulation of blood coagulation, it has also been shown to be a powerful agonist that can elicit a variety of cellular responses, including mitogenesis (Dery et al., 1998) . Several receptors for thrombin (PAR-1, PAR-3 and PAR-4) have been cloned and found to be members of the GPCR family. Activation of these receptors occurs through a ligand-mediated cleavage of an Arg-Ser bond in the NH 2 -terminal extracellular domain that generates a new NH 2 -terminus that functions as a tethered ligand. Like several other GPCR family members, deregulated expression of the PAR-1 receptor has been shown to be transforming as measured by its ability to stimulate focus formation in NIH3T3 cell assays (Whitehead et al., 1995a) . Although the mechanism by which PAR-1 transforms NIH3T3 cells has not yet been determined, there have been recent reports suggesting that GPCRs transform cells through stimulation of signaling pathways that are regulated by members of the Rho family of small GTPases (Zohn et al., 1998a) .
Rho family proteins constitute a large subfamily (14 mammalian members) of Ras-related GTPases whose activity is required for many aspects of cellular behavior (reviewed in Van Aelst and D'Souza-Schorey, 1997; Zohn et al., 1998b) . First, Rho family proteins have been shown to have an important role in regulating the actin cytoskeletal organization. For example, Cdc42 stimulates the appearance of ®lopodia, Rac1 causes lamellipodia formation and membrane ruing, and RhoA regulates the formation of actin stress ®bers and focal adhesions Nobes and Hall, 1995) . Second, Rho family proteins stimulate the activation of transcription factors and regulate gene expression. Signaling activities that have been attributed to Rho family members include activation of c-Jun NH 2 -terminal kinase (JNK), mitogen-activated protein kinase (MAPK) and its downstream target c-Jun (Coso et al., 1995; Minden et al., 1995; Olson et al., 1995; Westwick et al., 1998) , activation of the serum response factor (SRF: Hill et al., 1995; Westwick et al., 1998) , activation of the ternary complex factor protein Elk-1 (Whitmarsh et al., 1997) , and activation of NF-kB (Sulciner et al., 1996; Perona et al., 1997; Montaner et al., 1998) . Finally, a third function of Rho family proteins involves regulation of cell proliferation. RhoA, Rac1 and Cdc42 are required for cell cycle progression and can regulate transcription from the cyclin D1 promoter (Westwick et al., 1997 (Westwick et al., , 1998 . Aberrant activation of these three Rho family proteins, as well as their activators, causes growth transformation and promotes tumor cell invasion (Whitehead et al., 1997; Zohn et al., 1998b) .
Like the Ga subunits of heterotrimeric G proteins, Rho family proteins function as binary switches that cycle between a biologically active GTP-bound form and an inactive GDP-bound form (Bourne et al., 1990) . The ratio of active to inactive Rho in the cell is determined by several distinct classes of regulatory enzymes including guanine nucleotide exchange factors (GEFs) that activate Rho proteins by catalyzing the exchange of GDP for GTP, and GTPase activating proteins (GAPs) that promote GTP hydrolysis (Whitehead et al., 1997) . Additionally, the activation of GPCRs has been linked to the activation of Rho family proteins. For example, recent reports have identi®ed a mechanism by which Ga 13 -coupled GPCRs can cause activation of RhoA Hart et al., 1998) . The human p115-RhoGEF and its mouse homolog Lsc (Whitehead et al., 1996; Hart et al., 1996) contain a regulator of G protein signaling (RGS) domain that functions as a GTPase activating protein (GAP) and negative regulator of Ga 12 and Ga 13 . p115-RhoGEF/Lsc also contains a separate GEF domain speci®c for activation of RhoA. Ga 13 (but not Ga 12 ) binding to p115-RhoGEF causes activation of this GEF . Thus, a Ga 13 /p115-RhoGEF complex provides a direct link between GPCRs and RhoA.
In a screen for cDNAs whose expression causes focus formation in NIH3T3 cells we recovered a cDNA that encodes the full-length thrombin receptor PAR-1. The transforming activity of PAR-1 is attributable to the ectopic overexpression of the receptor rather than to an activating mutation. Although inhibitors of thrombin did not block PAR-1 transformation, a PAR-1 mutant that could not be cleaved by thrombin was impaired in transforming activity. We observed that PAR-1 has signaling and transforming activities that were similar to those seen with activated RhoA. We further observed that, like RhoA, PAR-1 induced the formation of stress ®bers, and that dominant negative RhoA blocked PAR-1 transformation. Finally, PAR-1 transformation was sensitive to pertussis toxin and to downregulation by the RGS domain of Lsc, implicating multiple Ga subunits in PAR-1 transformation. These results provide further evidence linking the GPCRs to signaling pathways regulated by the Rho GTPases and provide additional insights into the mitogenic signaling potential of this important family of receptors.
Results
The wild type PAR-1 receptor transforms NIH3T3 cells through a ligand-independent, yet cleavage-dependent, mechanism
We have screened a cDNA expression library derived from the mouse hematopoietic B6SutA 1 cell line for sequences that cause focus formation when expressed in NIH3T3 cells. In addition to three cDNAs that encode novel sequences, a cDNA encoding the thrombin-stimulated GPCR PAR-1 was identi®ed. Since we had isolated PAR-1 clones in similar screens of expression libraries derived from other hematopoietic cell lines (Whitehead et al., 1995a) , the PAR-1 clone was selected for further analysis. The sequences encoded by the transforming PAR-1 cDNA were identical to full-length, wild type mouse PAR-1 (not shown), thus indicating that transformation was attributable to overexpression of the receptor rather than to an activating mutation. Since PAR-1 is normally expressed in non-transformed NIH3T3 cells at low levels (not shown), deregulated expression of the receptor in native receptor expressing cells appears to be sucient for oncogenic activity. We determined that human wild type PAR-1 also exhibited transforming activity, indicating that this activity was not speciesspeci®c (not shown).
Next we wanted to determine whether transformation of NIH3T3 cells by PAR-1 occurs in an agonistdependent manner. Under normal physiological conditions, PAR-1 is activated by cleavage of the NH 2 -terminal extracellular domain by thrombin. The cleavage event generates a new NH 2 -terminus that functions as a`tethered' ligand for the receptor (Vu et al., 1991) . Although hirudin contains a thrombin binding site, and has been shown to be a potent antagonist for PAR-1 activation in other cell systems, it had a relatively small eect on the transforming potency of PAR-1 (Figure 1a To further address the dependence of PAR-1 transformation on ligand interactions, we generated and examined a derivative of PAR-1 that lacks a functional ligand cleavage site. For this analysis, we introduced a point mutation (R41A) into the cleavage recognition site of mouse PAR-1 (Coughlin, 1993) . Previous studies have shown that this mutation renders the receptor insensitive to ligand cleavage and activation (Vu et al., 1991) . In contrast to the inhibitor studies described above, this mutant lacked any detectable transforming activity (Figure 1c) . A Western blot analysis veri®ed comparable levels of expression of the wild type and mutant PAR-1 expression vectors (not shown). Thus, whereas PAR-1 mediated transformation is clearly dependent upon ligand engagement and cleavage, the relevant ligand does not appear to be thrombin.
PAR-1 and activated Rho behave similarly in transformation assays
We next wanted to determine the mechanism by which PAR-1 causes transformation. Previous studies have shown that thrombin stimulation can cause transient activation of the RhoA and Ras small GTPases (reviewed in Seasholtz et al., 1999) . Therefore, as a ®rst analysis we compared PAR-1 transforming activity with that of the constitutively activated, GTPasede®cient, mutants of RhoA and H-Ras in primary focus formation assays. RhoA(63L) and Ras(61L) exhibit distinct transforming activities when analysed
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A. in NIH3T3 mouse ®broblasts (Khosravi-Far et al., 1995) . We observed that the foci formed in NIH3T3 cells by expression of PAR-1 consists of small and compact, nonrefractile cells, and thus more closely resembled those formed by activated RhoA ( Figure  2a ). By contrast, foci that are induced by expression of Ras had a very distinct swirled morphology and consisted of highly refractile, spindle-shaped cells, and these foci are much larger and aggressive in growth than those seen with Rho or PAR-1.
We next compared the morphology of PAR-1 expressing cells, and cells that express activated derivatives of RhoA or Ras. For these analyses NIH3T3 cells were stably transfected with mammalian expression vectors that encode Ras(61L), RhoA(63L), PAR-1 or the empty vectors pZIP-NeoSV(x)1 (neomycin resistant) and pCTV3H (hygromycin resistant). Multiple (4100) G418-or hygromycin-resistant colonies were then selected and pooled together for analyses. As described previously, RhoA(63L)-expressing cells retained a cuboidal, non-refractile morphology and were indistinguishable from non-transfected or vector transfected cells when analysed at subcon¯uent densities ( Figure 2b ) (Khosravi-Far et al., 1995) . In contrast, H-Ras(61L)-expressing cells exhibited their typical refractile, elongated morphology. The morphology of PAR-1 transformed cells was identical to that of Rho transformed cells and was quite distinct from that of Ras-transformed cells. The focus and cellular morphology of PAR-1-transformed cells suggested that PAR-1 transformation was a consequence of RhoA, rather than Ras, activation.
We and others have observed previously that transforming derivatives of Rho family proteins and their activators (e.g., Vav, Mas, G2A) will cooperate with activated Raf-1 to cause potent focus formation in NIH3T3 cells Zohn et al., 1998a; Whitehead et al., 1998) . This cooperation re¯ects the fact that Raf-1 and Rho family proteins activate distinct signaling pathways that, when coordinately activated, lead to synergistic transforming activity. To further assess the transforming potential of PAR-1 we compared the abilities of RhoA(63L) and PAR-1 to cooperate with Raf(340D) in a primary focus formation assay. Raf(340D) is a weakly activated derivative of Raf-1 that exhibits relatively low focus forming activity when expressed alone in NIH3T3 cells . When co-transfected with either RhoA(63L) or PAR-1, Raf(340D) exhibited potent focus-forming activity (greater than ®vefold over additive; Figure 2c ). The morphology of the foci induced by Raf in cooperation with PAR-1 was identical to that seen in cooperation with RhoA ( Figure 2d ). The foci were large and swirled, were comprised of elongated, refractile cells, and were indistinguishable from foci induced by activated Raf or Ras when expressed alone (not shown). In contrast, foci induced by Raf in cooperation with activated Rac1(61L) or Mas (a Rac activator) are distinct in appearance (Zohn et al., 1998a ) from those of PAR-1 and Raf-1, suggesting that PAR-1 is not an activator of Rac.
Stable expression of PAR-1 in NIH3T3 cells is sufficient to cause serum-and anchorage-independent growth
To further examine the eects of PAR-1 expression on the growth properties of NIH3T3 cells, we examined the stably selected cell lines that overexpressed PAR-1 for a loss of serum-and anchorage-dependent growth. Although cell populations expressing PAR-1 exhibited no obvious morphologic transformation when compared to cells transfected with vector alone (see Figure  2b ), the cells grew rapidly in low serum (2%; Figure  3a ) and exhibited signi®cant colony formation in soft agar ( Figure 3b ). This combination of eects on cell growth and morphology are reminiscent of what we observe with cells stably transfected with activated Rho family members. We conclude that PAR-1 expression disrupts the growth properties of NIH3T3 cells in a manner that is consistent with activation of Rho family members.
RhoA and PAR-1 cause similar changes in the actin cytoskeleton
We observed previously that PAE cells undergo discrete changes in their actin cytoskeleton organization when microinjected with expression plasmids that encode activated derivatives of Rho family members (Westwick et al., 1997 (Westwick et al., , 1998 Zohn et al., 1998a) . Cells that express activated RhoA exhibit enhanced actin stress ®ber formation, whereas cells that express activated Rac1 or CDC42Hs form lammelipodia and ®lopodia respectively. To determine if PAR-1 activated a speci®c Rho family protein, we examined the actin cytoskeleton of PAE cells that had been microinjected with an expression plasmid that encodes the full-length PAR-1 protein. We observed similar results with PAR-1 as we had previously seen with an activated derivative of RhoA. PAR-1 induced actin stress ®ber formation, but not lammelipodia or ®lopodia (Figure 4 ). This observation suggests that PAR-1 causes transformation of NIH3T3 cells by activation of RhoA, rather than Rac1 or Cdc42. 
PAR-1 requires RhoA for transformation
To directly assess whether RhoA function was required for PAR-1 transformation, we utilized a dominant negative mutant of RhoA. The RhoA(19N) dominant negative protein has been used widely and shown to be a speci®c inhibitor of RhoA-mediated functions (Feig, 1999) . We showed previously that the transforming activity of GPCRs can be substantially blocked by dominant-inhibitory versions of Rho family members (Zohn et al., 1998a) . Whereas expression constructs encoding RhoA(WT) and RhoA(19N) were not growth inhibitory when compared to vector controls (not shown) co-expression of PAR-1 with dominant-inhibitory RhoA dramatically reduced its transforming activity in a primary focus formation assay (470%; Figure 5 ). Co-expression of PAR-1 with wildtype RhoA or empty vector had no eect. These results strongly support a requirement for RhoA in PAR-1 transformation.
RhoA and PAR-1 exhibit overlapping, but distinct signaling profiles
If PAR-1 signaling activity in NIH3T3 cells is regulated exclusively via activation of RhoA regulated pathways, then there should be a precise convergence between the signaling pathways that are activated by RhoA and by PAR-1. Activated RhoA has been shown to stimulate transcription from a variety of promoter elements including the NFkB responsive element of the HIV LTR promoter, the cyclin D1 promoter, and a mutated version of the serum response element of the c-fos promoter that no longer binds TCFs (Westwick et al., 1997) . Therefore we determined if PAR-1 could stimulate transcription from these same promoters. For these analyses we utilized reporter constructs where luciferase expression was controlled by the cyclin D1 promoter or by minimal promoters containing recognition sites for SRF and NF-kB. NIH3T3 cells were cotransfected with activated RhoA(63L) or PAR-1, along with the indicated reporter plasmid (Figure 6 ). Both RhoA and PAR-1 showed greater than fourfold stimulation of NF-kB and SRE and a weak, twofold activation of the cyclin D1 promoter. We also determined if PAR-1 could activate the Elk-1 and cJun transcription factors by co-transfection of a plasmid in which the transactivation domain of Elk-1 or c-Jun is fused to the Gal4 DNA binding domain (Gal4-Elk-1, Gal4-c-Jun), together with a second plasmid where luciferase gene expression is controlled by a minimal promoter that contains tandem Gal4 DNA binding sequences (5XGal4-luc). Whereas PAR-1 was a very poor activator of c-Jun, RhoA(63L) showed greater than sevenfold stimulation of the c-Jun reporter. In contrast, RhoA(63L) did not activate Elk-1 while PAR-1 showed a fourfold stimulation of the Elk-1 reporter. The fact that the PAR-1 and RhoA signaling pro®les do not precisely converge, and that PAR-1 can activate pathways that are not regulated by RhoA, suggests that PAR-1 may be activating RhoAindependent pathways. This possibility is consistent with the fact that PAR-1 exhibits a much greater focusforming activity that activated RhoA(63L).
Involvement of heterotrimeric G proteins in PAR-1 transformation
Multiple Ga subunits have been linked to PAR-1-mediated signaling and include the pertussin toxin (PTX) sensitive Ga i subtype responsible for the inhibition of adenylate cyclase and a PTX-insensitive Ga q subtype that links the receptor to phospholipase C activation (Seasholtz et al., 1999) . PAR-1 has also been shown to activate Ga 12 and Ga 13 . Since our analyses indicated that PAR-1 transformation is RhoA-dependent, and we found that like PAR-1, Ga l , Ga 12 and Ga 13 promote stress ®ber formation in PAE cells, we assessed the contribution of these Ga subunits to PAR-1 transforming activity.
To address the role of a PTX-sensitive Ga subunit in PAR-1 transformation, we conducted a focus forma- Figure 4 PAR-1 induces actin stress ®ber formation in PAE cells. PAE cells were microinjected with an expression construct encoding PAR-1 along with GFP as described in Materials and methods. Cells were serum-starved following injection and actin was stained with RITC-phalloidin. Microinjected cells were identi®ed by expression of GFP. Bar indicates 10 nm tion assay with PAR-1 in the presence of PTX ( Figure  7a ). For these analyses, we included Ras as a potential negative control, since Ras has been positioned downstream of heterotrimeric G protein signaling and thus, should be insensitive to the eects of PTX. We also included the Mas GPCR, whose transforming activity may be due to the coordinate activation of Ga i and Ga q . PTX dramatically reduced the transforming activity of both Mas and PAR-1 thus implicating G proteins of the Ga i subtypes as targets for their transforming activity. As expected, PTX had no eect on the transforming activity of Ras, indicating that the inhibition of PAR-1 and Mas was not due to a nonspeci®c inhibitory activity.
We next addressed a contribution of Ga 12 , and Ga 13 . For these analyses, we utilized an expression vector that encoded the isolated RGS domain of Lsc, which has been shown to be a GAP for Ga 12 , and Ga 13 . Expression of LscRGS speci®-cally blocks transformation mediated by Ga 12 or Ga 13 , and also blocks transformation via G2A, a GPCR that causes transformation by activation of RhoA (Zohn et al., 2000) . Co-expression of Lsc RGS strongly suppressed focus formation by both mouse and human PAR-1 (Figure 7b) . Thus, PAR-1 transformation appears to be dependent on Ga 12 and/or Ga 13 . This raises the possibility that PAR-1 causes activation of Rho via Ga 13 -dependent activation of an Lsc-related Rho GEF.
Discussion
We have identi®ed a cDNA derived from the B6SutA 1 murine hematopoietic cell line that is strongly transforming when expressed in NIH3T3 cells. This cDNA encodes full-length, wild type mouse thrombin receptor PAR-1. That PAR-1 can function as an oncoprotein is consistent with a role for thrombin in the regulation of cell proliferation in ®broblasts and other cell types (Dery et al., 1998; Van ObberghenSchilling et al., 1998) . In addition to its focus-forming activity, stable expression of the PAR-1 cDNA in NIH3T3 cells promoted growth in low serum and anchorage-independent growth. We determined that PAR-1 transformation was mediated, in part, by activation of Ga i and Ga 12 /Ga 13 to cause activation of the RhoA small GTPase. Thus, PAR-1 joins a growing subfamily of the GPCR's that harbor potent oncogenic potential when expressed in mammalian ®broblasts.
The lack of an activating mutation in the PAR-1 transforming sequence suggests that transformation is attributable to deregulated expression of the receptor. Interestingly, PAR-1 expression is detectable at low levels in non-transformed NIH3T3 cells, thus suggest- After drug selection, the cells were infected with varying doses of virus derived from empty vector or vector carrying mPAR-1 or hPAR-1 cDNAs. After 10 days post con¯uence the cultures were scored for foci greater than one mm diameter by microscopy, and stained with methylene blue for photography. The foci numbers are shown for each culture ing that increased expression of PAR-1 in native receptor expressing cells may be sucient for oncogenic transformation. Since several agonists for the PAR-1 receptor have been identi®ed and the mechanism of receptor activation has been determined, we also had the opportunity to determine whether PAR-1 transformation requires engagement by a ligand and/or proteolytic cleavage of the receptor. Introduction of a mutation in the NH 2 -terminus of the receptor that renders PAR-1 insensitive to proteolytic cleavage (Genda et al., 1999) completely abolished PAR-1 focus-forming activity, indicating that receptor cleavage was essential for PAR-1 transformation. However, we found that two inhibitors of extracellular thrombin (hirudin and PPACK) were completely ineective in blocking PAR-1 transforming activity, suggesting that thrombin is not the relevant ligand.
Although additional studies will be required to identify the ligand that is responsible for PAR-1 mediated transformation, possible candidates include the coagulation factors FXa and FVlla. Both of these proteases have been shown to activate PAR-1 in a thrombin independent manner (Camerer et al., 2000) . Thrombin stimulation has been shown to stimulate signaling pathways that promote the activation of RhoA and Ras (Seasholtz et al., 1999) . Thus, PAR-1 transformation may be caused by constitutive upregulation of these two small GTPases. Our analyses suggest that PAR-1 transformation is mediated primarily by activation of RhoA. First, the focus morphology of PAR-1 transformed cells was indistinguishable from that caused by activated RhoA(63L), and very distinct from that caused by activated Ras(61L). PAR-1-and Rho-induced foci consisted of small, tightly packed clusters of non-refractile cells, whereas Ras-induced foci were larger, more well spread, and contain highly refractile and elongated cells. Second, like RhoA(63L), PAR-1 caused a transformed phenotype that did not involve morphologic transformation, but did involve growth transformation, as measured by a reduced requirement for serum growth factors, and loss of density-and anchorage-dependent growth. In contrast, Ras-transformed NIH3T3 cells undergo both morphologic and growth transformation.
Additional evidence implicating RhoA in PAR-1 transformation comes from our determination that, like activated RhoA, microinjection of PAR-1 into PAE cells caused the induction of actin stress ®bers. This is similar to what we have observed for the G2A GPCR, a RhoA activator (unpublished observations), but distinct from the formation of lamellipodia caused by the Mas GPCR, an activator of Rac (Zohn et al., 1998a) . We also observed that dominant negative RhoA blocked PAR-1 transforming activity, indicating that RhoA activation is necessary for PAR-1 transformation. The mechanism through which PAR-1 may be enhancing RhoA activity remains unclear. We have examined levels of Rho-GTP in PAR-1 transformed NIH3T3 cells but have not been able to detect any consistent increases relative to vector controls (G Mahon, unpublished observations). Since highly transforming exchange factors for RhoA, such as Dbs and Dbl, only exhibit modest eects in such assays, this result may simply re¯ect a lack of sensitivity of this assay. Alternatively, RhoA activation by PAR-1 may be attributable to accelerated cycling by the GTPase rather than to discernible increases in steady-state levels of GTP loading.
Although our results clearly implicate RhoA as necessary for PAR-1 transformation, the biological activity of PAR-1 in NIH3T3 cells can not be accounted for by the exclusive activation of RhoA. Whereas PAR-1 and activated RhoA(63L) exhibited a common ability to activate several transcriptional pathways (SRF and NF-kB), there was not a precise convergence in their transcriptional pro®les. For example, RhoA(63L) did not activate the Elk-1 transcription factor, while PAR-1 exhibited signi®cant stimulation of Elk-1. This additional activity of PAR-1 is not surprising in that PAR-1 activation can lead to stimulation of Gbg, and consequently, activation of the Ras/ERK pathway (van Corven et al., 1993) . Furthermore, PAR-1 exhibits a much greater focus forming activity than activated RhoA(63L), indicating that RhoA-dependent and -independent signaling activities are required to promote full PAR-1 transformation.
There is considerable evidence for GPCR activation of RhoA via multiple Ga subunits, including Ga l , Ga q , Ga 12 and Ga 13 (Seasholtz et al., 1999) . Our observation that PAR-1 transformation is PTX sensitive provides evidence for involvement of Ga l . PTX-sensitive GPCR activation of RhoA has been described previously (Fareed et al., 1999; Betuing et al., 1998) . Additionally, we determined that co-expression of the isolated Lsc RGS domain blocked PAR-1 transforming activity, thus implicating Ga 12 and/or Ga 13 in PAR-1 activation of RhoA. Thrombin activation of Ga 12 and Ga 13 has been observed previously (Tordai et al., 1993) . Finally, we have previously observed that activated Ga q also induces stress ®ber formation in the same PAE cells that we have used for our PAR-1 actin cytoskeletal analyses. Thus, PAR-1 activation of Ga q may also contribute to activation of RhoA. Therefore, PAR-1 activation of RhoA may involve the activation of at least four distinct Ga subunits. While Lsc/p115 RhoGEF (and possibly PDZ-RhoGEF) can connect Ga 13 to RhoA, the identity of Rho GEFs that link Ga l , Ga q or Ga 12 to RhoA has not been established.
In summary, we have determined that chronic PAR-1 mediated signaling can cause growth transformation. This observation is consistent with observations that peptides that correspond to the tethered ligand have been shown to stimulate mitogenic responses in endothelial cells, smooth muscle cells, neural cells and ®broblasts. PAR-1 joins a small subfamily of the GPCRs (including Mas and G2A) that share the unique ability to transform NIH3T3 cells. Although the transforming activity of each of these receptors requires Rho function, the particular substrate that is activated by the receptors can dier. Mas transformation occurs in a Racl dependent manner (Zohn et al., 1998a) , while G2A transformation is mediated by RhoA (Zohn et al., 2000) . In the case of PAR-1, the identi®cation of a substrate that can mediate its transforming activity in native receptor expressing cells seems particularly important. Overexpression of the thrombin receptor has been reported in some human cancers and has been associated with increased tumor cell invasiveness (Macey et al., 1996; Even-Ram et al., 1998; Henrikson et al., 1999) . In this current study we have presented additional evidence of the broad oncogenic potential of this receptor when it is expressed in an inappropriate context. Thus, while most studies of thrombin have concentrated on its normal physiological role in wound healing and blood clotting, it is becoming increasingly clear that studies of thrombin and its receptor can also provide valuable insights into novel mechanisms of cellular transformation.
Materials and methods

Molecular constructs
The pAX142 and pCTV3H mammalian expression vectors have been described previously (Whitehead et al., 1995b) . pCTV3-par-1 encodes a full-length, wild type version of the PAR-1 receptor that was isolated from a screen for cDNAs whose deregulated expression causes focus formation in NIH3T3 cells. pAX142-par-1 was made by isolating the MluI/BsiW1 insert from pCTV3-par-1 and ligating into pAX142 digested with MluI/BsiWI. An Arg41?Ala41 mutation was introduced into the thrombin cleavage site of full-length PAR-1 (pAX142-par-1(R41A)) by PCR-based sitedirected mutagenesis. All fragments that were synthesized by polymerase chain sequence were sequenced in their entirety to ensure that only speci®ed mutations had occurred. Automated sequencing was provided by the UMDNJ Molecular Resource Facility. The murine PAR-1 cDNA used to test the eect of LscRGS was obtained from a 32D cell cDNA library (Whitehead et al., 1995a) . It was inserted into a pCTV3 derivative retroviral vector and stably expressed in NIH3T3 cells by infection. The human PAR-1 cDNA was provided by Ellen Van Obberghen-Schilling (Centre de Biochimie, CNRS, France). The LscRGS construct has been described previously (Zohn et al., 2000) . It was inserted into a pCTV derivative vector and stably expressed by infection. The pAX142 constructs encoding RhoA(WT), RhoA(19), Ras(61L), Mas, and the pZIP-NeoSV(x)1 constructs encoding RhoA(63L), Ras(61L), and Raf(340D), have been described previously (Khosravi-Far et al., 1995; Zohn et al., 1998a) . The reporter constructs utilized in the luciferase-coupled transcriptional assays have also been described: Gal4-Elk-1 and 5XGal4-luc, Gal-Jun(1-223), cyclin D1(-963)-Luc, HIVluc, and (SREm) 2 -luc (Westwick et al., 1997) .
Cell culture, transfection and transformation assays NIH3T3 and BOSC23 cells were maintained in Dulbecco's modi®ed Eagle medium (DMEM; high glucose) supplemented with 10% calf serum and 10% fetal calf serum respectively. Primary focus-formation assays were performed in NIH3T3 cells exactly as described (Clark et al., 1995) . Brie¯y, NIH3T3 cells were transfected by calcium phosphate co-precipitation in conjunction with a glycerol shock. Focus formation was scored at 14 days. Cognate empty vectors for each construct were employed as controls. NIH3T3 cell lines that stably express pCTV3, pCTV3-par-1, pZIP-rhoA(63L) or pZIP-H-ras(61L) were generated by calcium phosphate transfection. Following transfection, cells were selected for 14 days in growth medium supplemented with hygromycin (200 mg/ml: pCTV3) or G418 (400 mg/ml: pZIP-NeoSV9x)1). Multiple drug-resistant colonies (4100) were pooled together to establish cell lines for the transformation assays. The growth properties of NIH3T3 cells expressing pCTV3, PAR-1, RhoA(63L) or Ras(61L) were compared in their abilities to proliferate in a low concentration of serum (2%) or soft agar by procedures that we have described previously. All assays for transformation were performed in triplicate. Hirudin (Sigma) treatment was done for the entire course of the assay, with fresh inhibitor added with each growth medium change done every other day.
Transient expression reporter gene assays
For transient reporter assays, NIH3T3 cells were transfected by calcium phosphate co-precipitation, allowed to recover for 30 h and starved in DMEM with 0.5% newborn calf serum for 14 h before lysate preparation. Analysis of luciferase expression in transiently transfected NIH3T3 cells was performed as described using Enhanced Chemiluminescent reagents and a Monolight 2010 luminometer (Analytical Luminescence, San Diego, CA, USA). All assays were performed in triplicate.
Analysis of actin stress fiber formation
Analysis of actin stress ®bers was performed as described previously (Westwick et al., 1997) . Brie¯y, porcine aortic endothelial (PAE) cells were injected in the nucleus with pAX142 or pAX142-par-1 (25 mg/ml). Subsequently, cells were starved in serum-free growth medium for 12 ± 14 h and ®xed in 4% formaldehyde as described previously. Polymerized actin was stained with pahlloidin.
